Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$19.75
-0.46-2.28%
At close: -
$19.75
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
NewAmsterdam Pharma Co Analyst Ratings and Price Targets | NASDAQ:NAMS | Benzinga
NewAmsterdam Pharma Co NV has a consensus price target of $36 based on the ratings of 13 analysts. The high is $52 issued by Scotiabank on February 27, 2025. The low is $19 issued by SVB Leerink on December 20, 2022. The 3 most-recent analyst ratings were released by Needham, Stifel, and Needham on June 12, 2025, June 10, 2025, and May 8, 2025, respectively. With an average price target of $41.33 between Needham, Stifel, and Needham, there's an implied 109.28% upside for NewAmsterdam Pharma Co NV from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Stifel
Scotiabank
RBC Capital
RBC Capital
1calculated from analyst ratings
Analyst Ratings for NewAmsterdam Pharma Co
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/12/2025 | Buy Now | 102.53% | Needham | Serge Belanger69% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 06/10/2025 | Buy Now | 122.78% | Stifel | James Condulis51% | → $44 | Initiates | → Buy | Get Alert |
| 05/08/2025 | Buy Now | 102.53% | Needham | Serge Belanger69% | $42 → $40 | Maintains | Buy | Get Alert |
| 04/08/2025 | Buy Now | 112.66% | Needham | Serge Belanger69% | $42 → $42 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 163.29% | Scotiabank | George Farmer41% | $47 → $52 | Maintains | Sector Outperform | Get Alert |
| 02/27/2025 | Buy Now | 112.66% | Needham | Serge Belanger69% | $46 → $42 | Maintains | Buy | Get Alert |
| 01/28/2025 | Buy Now | 102.53% | RBC Capital | Brian Abrahams49% | $40 → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 01/24/2025 | Buy Now | 102.53% | RBC Capital | Leonid Timashev42% | $40 → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 01/14/2025 | Buy Now | 143.04% | HC Wainwright & Co. | Ed Arce63% | $48 → $48 | Reiterates | Buy → Buy | Get Alert |
| 12/30/2024 | Buy Now | 143.04% | HC Wainwright & Co. | Ed Arce63% | → $48 | Initiates | → Buy | Get Alert |
| 12/11/2024 | Buy Now | 137.97% | Scotiabank | George Farmer41% | $35 → $47 | Maintains | Sector Outperform | Get Alert |
| 12/05/2024 | Buy Now | 82.28% | Needham | Serge Belanger69% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 11/21/2024 | Buy Now | 82.28% | Needham | Serge Belanger69% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | 82.28% | Needham | Serge Belanger69% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2024 | Buy Now | 82.28% | Needham | Serge Belanger69% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 09/23/2024 | Buy Now | 87.34% | Piper Sandler | Yasmeen Rahimi60% | $37 → $37 | Reiterates | Overweight → Overweight | Get Alert |
| 09/05/2024 | Buy Now | 56.96% | RBC Capital | Leonid Timashev42% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 08/28/2024 | Buy Now | 82.28% | Needham | Serge Belanger69% | → $36 | Initiates | → Buy | Get Alert |
| 07/30/2024 | Buy Now | 56.96% | RBC Capital | Leonid Timashev42% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 06/07/2024 | Buy Now | 56.96% | RBC Capital | Leonid Timashev42% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 05/15/2024 | Buy Now | — | TD Cowen | Tyler Van Buren44% | — | Initiates | → Buy | Get Alert |
| 03/14/2024 | Buy Now | 77.22% | Scotiabank | George Farmer41% | → $35 | Initiates | Sector Outperform → Sector Outperform | Get Alert |
| 03/13/2024 | Buy Now | 77.22% | Scotiabank | George Farmer41% | → $35 | Initiates | → Sector Outperform | Get Alert |
| 02/29/2024 | Buy Now | 56.96% | RBC Capital | Leonid Timashev42% | $25 → $31 | Maintains | Outperform | Get Alert |
| 01/18/2024 | Buy Now | 51.9% | Guggenheim | Debjit Chattopadhyay55% | → $30 | Initiates | → Buy | Get Alert |
| 01/16/2024 | Buy Now | 87.34% | Piper Sandler | Yasmeen Rahimi60% | → $37 | Initiates | → Overweight | Get Alert |
| 10/30/2023 | Buy Now | 26.58% | RBC Capital | Leonid Timashev42% | → $25 | Initiates | → Outperform | Get Alert |
| 04/03/2023 | Buy Now | 11.39% | Credit Suisse | Judah Frommer65% | $21 → $22 | Maintains | Outperform | Get Alert |
| 01/06/2023 | Buy Now | 6.33% | Credit Suisse | Judah Frommer65% | → $21 | Initiates | → Outperform | Get Alert |
| 12/20/2022 | Buy Now | -3.8% | SVB Leerink | Roanna Ruiz36% | → $19 | Initiates | → Outperform | Get Alert |
| 12/19/2022 | Buy Now | — | William Blair | Matthew Phipps10% | — | Initiates | → Outperform | Get Alert |
| 12/19/2022 | Buy Now | 21.52% | Jefferies | Dennis Ding17% | → $24 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for NewAmsterdam Pharma Co (NAMS) stock?
The latest price target for NewAmsterdam Pharma Co (NASDAQ:NAMS) was reported by Needham on June 12, 2025. The analyst firm set a price target for $40.00 expecting NAMS to rise to within 12 months (a possible 102.53% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NewAmsterdam Pharma Co (NAMS)?
The latest analyst rating for NewAmsterdam Pharma Co (NASDAQ:NAMS) was provided by Needham, and NewAmsterdam Pharma Co reiterated their buy rating.
When was the last upgrade for NewAmsterdam Pharma Co (NAMS)?
There is no last upgrade for NewAmsterdam Pharma Co
When was the last downgrade for NewAmsterdam Pharma Co (NAMS)?
There is no last downgrade for NewAmsterdam Pharma Co.
When is the next analyst rating going to be posted or updated for NewAmsterdam Pharma Co (NAMS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NewAmsterdam Pharma Co, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NewAmsterdam Pharma Co was filed on June 12, 2025 so you should expect the next rating to be made available sometime around June 12, 2026.
Is the Analyst Rating NewAmsterdam Pharma Co (NAMS) correct?
While ratings are subjective and will change, the latest NewAmsterdam Pharma Co (NAMS) rating was a reiterated with a price target of $40.00 to $40.00. The current price NewAmsterdam Pharma Co (NAMS) is trading at is $19.75, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
